Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3953  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
  »  Article in PDF (584 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  References
 »  Article Figures

 Article Access Statistics
    Viewed1510    
    Printed34    
    Emailed0    
    PDF Downloaded43    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
NEUROIMAGES
Year : 2017  |  Volume : 65  |  Issue : 1  |  Page : 220

Posterior reversible encephalopathy syndrome after high-dose cytarabine in acute myelogenous leukemia


1 Department of Neurology, University of Missouri-Columbia, Columbia, Missouri, USA
2 Department of Emergency Medicine, University of Missouri-Columbia, Columbia, Missouri, USA

Date of Web Publication12-Jan-2017

Correspondence Address:
Dr. Christopher R Newey
Department of Neurology, One Hospital Drive, Columbia, Missouri – 65212
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.198171

Rights and Permissions



How to cite this article:
Newey CR, Chandrasekaran PN, Mohebbi MR. Posterior reversible encephalopathy syndrome after high-dose cytarabine in acute myelogenous leukemia. Neurol India 2017;65:220

How to cite this URL:
Newey CR, Chandrasekaran PN, Mohebbi MR. Posterior reversible encephalopathy syndrome after high-dose cytarabine in acute myelogenous leukemia. Neurol India [serial online] 2017 [cited 2021 Jan 18];65:220. Available from: https://www.neurologyindia.com/text.asp?2017/65/1/220/198171


A 68-year-old female patient with acute myeloid leukemia (AML), who was being administered high-dose cytarabine (HiDAC), presented with ataxia, dysarthria, and a platelet count of 10 k/uL. Computed tomography of the head showed scattered evidence of cortical and subarachnoid hemorrhage [Figure 1]a, solid arrow]. Magnetic resonance imaging of the brain showed bilateral, posterior subcortical white matter hyperintense lesions [Figure 1]b, dashed arrow]. She had neither evidence of associated blood pressure lability or kidney failure, nor had undertaken immunomodulatory therapy.
Figure 1: (a) Computed tomography of the head showing scattered cortical subarachnoid hemorrhage (solid arrow). (b) Magnetic resonance imaging of the brain showing hyperintense lesions predominantly posteriorly on T2 images (left) and fluid-attenuated inversion recovery images (right, dashed arrow)

Click here to view


Posterior reversible encephalopathy syndrome is thought to be secondary to the loss of autoregulation of cerebral blood flow.[1],[2],[3] It is a well-described phenomenon in the setting of eclampsia, immunosuppression, and renal failure.[1] It is less described in induction chemotherapy with HiDAC for AML and should be recognized as a potential complication.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
 » References Top

1.
Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205-10.  Back to cited text no. 1
    
2.
Battipaglia G, Avilia S, Morelli E, Caranci F, Perna F, Camera A. Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML). Ann Hematol 2012;91:1327-8.  Back to cited text no. 2
    
3.
Lakhotia M, Pahadiya HR, Singh J, Bhansali S, Choudhary S, Jangid H. Posterior reversible encephalopathy syndrome as a rare presenting feature of acute intermittent porphyria. Neurol India 2015;63:607-9.  Back to cited text no. 3
[PUBMED]  Medknow Journal  


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow